Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2008 1
2010 2
2011 3
2012 2
2013 2
2014 1
2015 2
2016 3
2017 1
2018 1
2019 7
2020 11
2021 9
2022 11
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, Jefferson JA, Gipson PE, Rizk DV, Sedor JR, Simon JF, McCarthy ET, Brenchley P, Sethi S, Avila-Casado C, Beanlands H, Lieske JC, Philibert D, Li T, Thomas LF, Green DF, Juncos LA, Beara-Lasic L, Blumenthal SS, Sussman AN, Erickson SB, Hladunewich M, Canetta PA, Hebert LA, Leung N, Radhakrishnan J, Reich HN, Parikh SV, Gipson DS, Lee DK, da Costa BR, Jüni P, Cattran DC; MENTOR Investigators. Fervenza FC, et al. Among authors: barbour sj. N Engl J Med. 2019 Jul 4;381(1):36-46. doi: 10.1056/NEJMoa1814427. N Engl J Med. 2019. PMID: 31269364 Clinical Trial.
Evaluating a New International Risk-Prediction Tool in IgA Nephropathy.
Barbour SJ, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, Katafuchi R, Er L, Espino-Hernandez G, Kim SJ, Reich HN, Feehally J, Cattran DC; International IgA Nephropathy Network. Barbour SJ, et al. JAMA Intern Med. 2019 Jul 1;179(7):942-952. doi: 10.1001/jamainternmed.2019.0600. JAMA Intern Med. 2019. PMID: 30980653 Free PMC article.
An update on corticosteroid treatment for IgA nephropathy.
Ghaddar M, Barratt J, Barbour SJ. Ghaddar M, et al. Among authors: barbour sj. Curr Opin Nephrol Hypertens. 2023 May 1;32(3):263-270. doi: 10.1097/MNH.0000000000000881. Epub 2023 Mar 2. Curr Opin Nephrol Hypertens. 2023. PMID: 36866805 Review.
Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.
Cherney DZI, Dekkers CCJ, Barbour SJ, Cattran D, Abdul Gafor AH, Greasley PJ, Laverman GD, Lim SK, Di Tanna GL, Reich HN, Vervloet MG, Wong MG, Gansevoort RT, Heerspink HJL; DIAMOND investigators. Cherney DZI, et al. Among authors: barbour sj. Lancet Diabetes Endocrinol. 2020 Jul;8(7):582-593. doi: 10.1016/S2213-8587(20)30162-5. Lancet Diabetes Endocrinol. 2020. PMID: 32559474 Clinical Trial.
Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Floege J, Barbour SJ, Cattran DC, Hogan JJ, Nachman PH, Tang SCW, Wetzels JFM, Cheung M, Wheeler DC, Winkelmayer WC, Rovin BH; Conference Participants. Floege J, et al. Among authors: barbour sj. Kidney Int. 2019 Feb;95(2):268-280. doi: 10.1016/j.kint.2018.10.018. Kidney Int. 2019. PMID: 30665568 Free article.
Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification.
Sethi S, Beck LH Jr, Glassock RJ, Haas M, De Vriese AS, Caza TN, Hoxha E, Lambeau G, Tomas NM, Madden B, Debiec H, D'Agati VD, Alexander MP, Amer H, Appel GB, Barbour SJ, Caravaca-Fontan F, Cattran DC, Casal Moura M, D'Avila DO, Eick RG, Garovic VD, Greene EL, Herrera Hernandez LP, Jennette JC, Lieske JC, Markowitz GS, Nath KA, Nasr SH, Nast CC, Pani A, Praga M, Remuzzi G, Rennke HG, Ruggenenti P, Roccatello D, Soler MJ, Specks U, Stahl RAK, Singh RD, Theis JD, Velosa JA, Wetzels JFM, Winearls CG, Yandian F, Zand L, Ronco P, Fervenza FC. Sethi S, et al. Among authors: barbour sj. Kidney Int. 2023 Dec;104(6):1092-1102. doi: 10.1016/j.kint.2023.06.032. Epub 2023 Oct 5. Kidney Int. 2023. PMID: 37795587 Free article.
Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy.
Barbour SJ, Fervenza FC, Induruwage D, Brenchley PE, Rovin B, Hladunewich MA, Reich HN, Lafayette R, Aslam N, Appel GB, Zand L, Kiryluk K, Liu L, Cattran DC; MENTOR Trial Investigators. Barbour SJ, et al. Clin J Am Soc Nephrol. 2023 Oct 1;18(10):1283-1293. doi: 10.2215/CJN.0000000000000237. Epub 2023 Jul 20. Clin J Am Soc Nephrol. 2023. PMID: 37471101
PROTECTing the kidneys in IgA nephropathy.
Reich HN, Barbour SJ. Reich HN, et al. Among authors: barbour sj. Lancet. 2023 Dec 2;402(10417):2046-2047. doi: 10.1016/S0140-6736(23)02418-2. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931627 No abstract available.
Recognizing IgG4-related tubulointerstitial nephritis.
Mann S, Seidman MA, Barbour SJ, Levin A, Carruthers M, Chen LY. Mann S, et al. Among authors: barbour sj. Can J Kidney Health Dis. 2016 Jul 17;3:34. doi: 10.1186/s40697-016-0126-5. eCollection 2016. Can J Kidney Health Dis. 2016. PMID: 27429760 Free PMC article. Review.
60 results